Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

Both fourth quarter and full year 2010 net sales of Luvox CR include $2.0 million of revenue recorded as a result of a change in the timing of when revenue is recognized; the company now records Luvox CR sales upon shipment to distributors net of estimated returns.  The profit associated with this change has been excluded from the company's fourth quarter and full year 2010 adjusted net income.

"In 2010, our first full year of profitability, our progress included strengthening our balance sheet, enhancing our commercial business management team, significantly increasing Xyrem sales, and broadening our patent protection for sodium oxybate," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "We look forward to improving our performance in 2011, as we continue to grow and protect our Xyrem business and advance our intranasal clonazepam product candidate for acute repetitive seizures in epilepsy patients."

Research and development expenses for the fourth quarter of 2010 were $4.1 million, compared to $6.3 million for the fourth quarter of 2009.  Research and development expenses in 2010 were $25.6 million, compared to $36.6 million for 2009.  

Selling, general and administrative expenses for the fourth quarter of 2010 were $17.1 million, compared to $15.7 million for the fourth quarter of 2009.  In 2010, selling, general and administrative expenses were $69.0 million, compared to $58.7 million for 2009.

Interest expense for the fourth quarter of 2010 was $1.1 million, compared to $5.8 million for the prior year period.  Interest expense in 2010 was $12.7 million, compared to $22.8 million in 2009.  As of December 31, 2010, cash and cash equivalents were $44.8 million, an increase from $22.9 million at September 30, 2010.

2011 Financial GuidanceJazz Pharmaceuticals is providing full year 2011 financial guidance as follows:-- Total product sales

$ 232 - 245 mil
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Investor-Edge has initiated ... ZGNX ), Eli Lilly and Company (NYSE: LLY ... SNY ), and Novartis AG (NYSE: ... accessed at: http://investor-edge.com/register . On Friday, December ... the Dow Jones Industrial Average lost 1.79%, to finish the ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
(Date:12/13/2014)... Ala. , Dec. 12, 2014 ... purchased the HiSeq X Ten sequencing system manufactured ... enable HudsonAlpha to produce and analyze genomic data ... stems from the Institute,s commitment to research programs ... The HiSeq X Ten provides unprecedented capacity, speed ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... CHAPEL HILL -- When pregnant women are at high risk ... has been shown to reduce the babys chances of having ... multiple injections of corticosteroids, and a new study shows that ... of cerebral palsy among children of these mothers. , Our ...
... the great questions of neurobiology, how the brain is ... a young French scientist in an award winning project ... European Heads of Research Councils (EuroHORCS). Sonia Garel ... annually to young scientists, to pursue her ground breaking ...
... to low-glycemic carbs prevents the lethal illness, study finds ... in quick-burning carbohydrates may cause fatty liver disease, which ... a study in mice by researchers at Children,s Hospital ... it may mean that fatty liver disease can be ...
... New guidelines on the diagnosis and management of cows ... Disease in Childhood, are set to improve the standard ... food allergy in children.1 The Guidelines for the Diagnosis ... extensively hydrolysed (eHF) and amino acid-based formulas (AAF), and ...
... been awarded a National Institutes of Health (NIH) Directors ... is one of 12 recipients nationwide to win the ... award is designed to support individual scientists of exceptional ... biomedical and behavioral research. The term pioneering is used ...
... the review of approximately 12,000 emergency diagnostic imaging exams ... the midst of our research, a vigorous national debate ... prior to independent call, said Richard B. Ruchman, MD, ... and subsequently approved a new requirement that would mandate ...
Cached Medicine News:Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:EURYI project to understand how the brain wires during embryogenesis 2Health News:Diet Change Can Curb Fatty Liver Disease 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Decision-making by residents on-call has 'miniscule' negative impact on patient care 2
... is a hospital grade Nd: YAG laser ... precise, reliable means for performing posterior capsulotomy, ... can be used for the treatment of ... (posterior capsulotomy), and closed-angle glaucoma (iridotomy). , ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... a high-end, mobile ultrasound imaging system. Its ... tremendous amount of processing power for generating ... Ultrasonix imaging systems provide excellent image quality ... Pulsed Doppler, Color Doppler Color Angio, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: